The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000852358p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
25/06/2026
Date registered
Help: Date registered
13/07/2026
Date last updated
Help: Date last updated
13/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
13/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Intraocular Pressure Outcomes with Scleral Indentation Following Intravitreal Injection: A Clinical Crossover Trial in Patients Receiving Routine Intravitreal Anti-VEGF Injections
Scientific title
Intraocular Pressure Outcomes with Scleral Indentation Following Intravitreal Injection: A Clinical Crossover Trial in Patients Receiving Routine Intravitreal Anti-VEGF Injections
Additional trial identifiers [1] 317710 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Proliferative diabetic retinopathy 342572 0
Neovascular age-related macular degeneration 342573 0
Macular oedema 342576 0
Condition category
Condition code
Eye 338724 338724 0 0
Diseases / disorders of the eye
Metabolic and Endocrine 338843 338843 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Patients who normally receive intravitreal injections will be randomised to receive either scleral indentation or standard care (no indentation) at two of their treatment visits and standard care at two of their visits in a randomised order. There are four possible treatment sequences to which participants may be randomised: Sequence A (Indentation, Standard Care, Indentation, Standard Care), Sequence B (Standard Care, Indentation, Standard Care, Indentation), Sequence C (Indentation, Indentation, Standard Care, Standard Care), or Sequence D (Standard Care, Standard Care, Indentation, Indentation). Treatment visit frequency will be individualised based on the ocular condition being treated (typically 8-12 weekly intervals).

In this study, scleral indentation will involve continuous compression of both the injection site and corneal limbus for 20 seconds, with the swab applied parallel to the injection site and limbus and force applied toward the limbus. The swab is soaked in 0.4% oxybuprocaine hydrochloride for 5-10 seconds prior. The amount of pressure applied should be sufficient to create a visible circular indentation of the globe.The indentation will be applied by the ophthalmologist who administered the intravitreal injection, who will be timed by an assistant (e.g. assisting nurse).
Intervention code [1] 334545 0
Treatment: Other
Description of the comparator or control
This is a clinical crossover study, in which patients will act as their own control. The control group will receive routine intravitreal injection without scleral indentation.
Control group
Active

Outcomes
Primary outcome [1] 345935 0
Change in intraocular pressure (intraocular pressure at 60 seconds post-injection +/- indentation compared to intraocular pressure immediately prior to injection).
Timepoint [1] 345935 0
60 seconds post-injection +/- indentation.
Secondary outcome [1] 463823 0
Discomfort.
Timepoint [1] 463823 0
Participant asked to provide subjective rating (using Numerical Pain Rating Scale) for overall discomfort throughout the procedure at 1-2 minutes post-injection.

Eligibility
Key inclusion criteria
• Aged at least 18 years.
• Receiving routine intravitreal anti-VEGF injections for a TGA-approved indication, expected to continue for at least another 4 injections.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Inability to provide informed consent (including cognitive impairment impairing capacity and insufficient English language proficiency)
• Active ocular infection or inflammation, including endophthalmitis, keratitis, significant uveitis, or severe conjunctivitis.
• Any ocular condition where scleral indentation may be unsafe or inappropriate, such as severe scleral thinning, scleritis, significant scleral buckle- related concerns, or known globe fragility.
• Prior allergic reaction to oxybuprocaine.


Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer-generated random sequence.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
A sample size of 59 participants has been estimated using the standard formula for a two-treatment crossover trial, for a minimum detectable difference of 5 mmHg, with 90% power, a = 0.05, and standard deviation of 11.84 mmHg. No estimates of within-subject variability are available from the published literature (there have been no prior crossover studies of intraocular pressure following intravitreal injection). Instead, a pooled inter-patient standard deviation (of immediate post-injection intraocular pressure) has been calculated from the meta-analytic data provided by de Vries et al., 2020 and used as a conservative surrogate estimate (within-subject variability is expected to be less than the inter-subject variability across the multiple studies included in this calculation). To account for attrition (10-20%), 70-80 participants will be invited to participate in the research, with an aim to achieve an equal number of participants in each of the four possible treatment sequences. These will represent consecutively consenting patients recruited by each participating ophthalmologist.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 322251 0
Self funded/Unfunded
Name [1] 322251 0
Country [1] 322251 0
Primary sponsor type
University
Name
UNSW
Address
Country
Australia
Secondary sponsor category [1] 325162 0
None
Name [1] 325162 0
Address [1] 325162 0
Country [1] 325162 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320774 0
The University of New South Wales Research Ethics Committee A
Ethics committee address [1] 320774 0
Ethics committee country [1] 320774 0
Australia
Date submitted for ethics approval [1] 320774 0
29/06/2026
Approval date [1] 320774 0
Ethics approval number [1] 320774 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151574 0
Dr Zayn Al-Timimi
Address 151574 0
University of New South Wales Rural Clinical School, 345 Pacific Hwy, Coffs Harbour, NSW 2450
Country 151574 0
Australia
Phone 151574 0
+61 2 9348 0390
Fax 151574 0
Email 151574 0
Contact person for public queries
Name 151575 0
Zayn Al-Timimi
Address 151575 0
University of New South Wales Rural Clinical School, 345 Pacific Hwy, Coffs Harbour, NSW 2450
Country 151575 0
Australia
Phone 151575 0
+61 2 6652 0411
Fax 151575 0
Email 151575 0
Contact person for scientific queries
Name 151576 0
Zayn Al-Timimi
Address 151576 0
University of New South Wales Rural Clinical School, 345 Pacific Hwy, Coffs Harbour, NSW 2450
Country 151576 0
Australia
Phone 151576 0
+61 2 6652 0411
Fax 151576 0
Email 151576 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.